---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-047913"
form_type: "8-K"
ticker: "SWKHL"
cik: "0001089907"
company_name: "SWK Holdings Corp"
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:14:05.192733+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# SWK Holdings Reports Q3 2024 Net Income of $3.5 Million, Revenue Up 15.6%

## Summary
- Q3 2024 GAAP net income was $3.5 million, compared to $4.5 million in Q3 2023.
- Total revenue increased 15.6% to $10.4 million, driven by finance receivables segment.
- Net finance receivables grew 14.4% to $255.9 million as of September 30, 2024.
- Closed $11.0 million royalty financing with Relief Therapeutics and $25.7 million amendment with Eton Pharmaceuticals.
- GAAP book value per share rose 3.7% to $22.94; repurchased ~340,000 shares YTD for $5.8 million.

## SEC filing metadata
- accession: 0001628280-24-047913
- form_type: 8-K
- ticker: SWKHL
- cik: 0001089907
- company_name: SWK Holdings Corp
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1089907/000162828024047913/0001628280-24-047913-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1089907/000162828024047913/swkh-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-047913
- JSON: https://secwatch.observer/filing/0001628280-24-047913.json
- Plain text: https://secwatch.observer/filing/0001628280-24-047913.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.